NK cell engagers gain traction on broader bispecifics momentum
NK cell engagers emerge as a budding innate immune modality in immuno-oncology’s second wave
Growing confidence in NK cell therapies, the T cell engager flood and promising early data drive NK cell engager innovation.
While T cell engagers are flooding pipelines, a growing number of biotechs are betting on the closely-related NK cell engager structure as a safer way to redirect immune cells to tumors.
Pharmas — nearly all of which have jumped on the T cell engager bandwagon — are also testing the waters of the NK cell-targeting counterparts through a spate of recent deals.
The concept of using a bispecific antibody to activate NK cells and draw them to a tumor isn’t new, but the timing might be right for the therapeutic class to take off.
Affimed N.V. (NASDAQ:AFMD) began working on NK cell engager technology long before bispecific antibodies became an industry favorite among modalities, launching its first clinical trial over a decade ago. But there